Megapharm Ltd. entered into distribution and licensing agreement with MolMed SpA, for the supply, registration, promotion and distribution of MolMed's Zalmoxis in Israel. Zalmoxis is conditionally authorized by the European Commission for adult patients affected by leukaemia or other high- risk haematological malignancies, and is the first patient -specific cell therapy used in combinatio with haplo-dentical haematopoietic stem cell transplant (haplo- HSCT). Under the terms the agreement, Zalmoxis will be distributed and marketed by Megapharm, once approved by the Israeli Ministry of Health (MOH) and included in the Israeli National Health Basket of drugs by the MOH. Megapharm will be responsible for conducting all regulatory activities after marketing authorization in Israel, including market access and price & reimbursement. Earlier, on December 1, 2016, MolMed and Megapharm have entered into a term sheet for supply, registration, promotion and distribution of Zalmoxis in Israel. This agreement enables Megapharm and MolMed to commercialize Zalmoxis in Israel.